<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="monograph-family" /><meta name="keywords" content="Anticoagulants: parenteral; Heparin; Thrombosis; Thrombosis: deep-vein; Deep-vein thrombosis; Pulmonary: embolism; Thromboembolism: pulmonary; Protamine sulphate" /><meta name="IX" content="Anticoagulants: parenteral; Heparin; Thrombosis: deep-vein; Deep-vein thrombosis; Pulmonary: embolism; Thromboembolism: pulmonary; Protamine sulphate" /><meta name="IXN" content="Thrombosis" /><title>Heparin: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="11290.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="11290.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=11290.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="1002.htm">2 Cardiovascular system</a> &gt; <a href="2760.htm">2.8 Anticoagulants and protamine</a> &gt; <a href="2761.htm">2.8.1 Parenteral anticoagulants</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="2761.htm" title="Previous: 2.8.1 Parenteral anticoagulants">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="2762.htm" title="Next: HEPARIN">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_11290">Heparin</h1><?highlighter on?><div id="pC" class="jN"><div><p><b><span>Heparin</span></b> initiates anticoagulation rapidly but has a short duration
of action. It is often referred to as ‘<b>standard</b>’
or ‘<b>unfractionated heparin</b>’ to distinguish it from
the <b>low molecular weight heparins</b> (see <a title="monograph-family: Low molecular weight heparins" href="2772.htm#_2772">Low Molecular Weight Heparins</a>), which have a longer duration of action. Although
a low molecular weight heparin is generally preferred for routine
use, unfractionated heparin can be used in those at high risk of bleeding
because its effect can be terminated rapidly by stopping the infusion.</p><div id="_208591"><div class="cAZ"><h2>Treatment</h2> <p class="cAX">For the initial treatment
of deep-vein thrombosis and pulmonary
embolism a low molecular weight heparin is used; alternatively, unfractionated <span>heparin</span> is given as an intravenous loading dose, followed
by continuous intravenous infusion (using an infusion pump) or by
intermittent subcutaneous injection. Intermittent intravenous injection
of unfractionated heparin is no longer recommended. An oral anticoagulant
(usually warfarin, <a title=" Oral anticoagulants" href="2791.htm#_2791">section 2.8.2</a>) is started at the same time as unfractionated
or low molecular weight heparin (the heparin needs to be continued
for at least 5 days and until the INR is ≥2 for at least 24 hours). <span id="_11290.3"></span>Laboratory monitoring for unfractionated heparin, preferably
on a daily basis, is essential; determination of the activated partial
thromboplastin time (APTT) is the most widely used measure (for unfractionated
heparin). A low molecular weight heparin or, in some circumstances,
unfractionated heparin is also used in regimens for the management
of myocardial infarction and unstable angina (<a title="BNF:sub-section: Management of myocardial infarction" href="60552.htm#_60552">section 2.10.1</a>).</p></div></div><div class="cAZ"><h2>Prophylaxis</h2> <p class="cAX">For details on the use of heparins
in the prophylaxis of venous thromboembolism see <a title="BNF:target-block: Prophylaxis of venous thromboembolism" href="208578.htm#_208581">section 2.8</a>.</p></div><div id="_11290.1"><div class="cAZ"><h2>Pregnancy</h2> <p class="cAX">Heparins are used for the management
of venous thromboembolism in pregnancy because they do not cross the
placenta. Low molecular weight heparins are preferred because they
have a lower risk of osteoporosis and of heparin-induced thrombocytopenia.
Low molecular weight heparins are eliminated more rapidly in pregnancy,
requiring alteration of the dosage regimen for drugs such as dalteparin,
enoxaparin, and tinzaparin; see also under individual drugs. Treatment
should be stopped at the onset of labour and advice sought from a
specialist on continuing therapy after birth.</p></div></div><div class="cAZ"><h2>Extracorporeal circuits</h2> <p class="cAX">Unfractionated <span>heparin</span> is also used in the maintenance of extracorporeal
circuits in cardiopulmonary bypass and haemodialysis.</p></div><div id="_11290.2"><div class="cAZ"><h2>Haemorrhage</h2> <p class="cAX">If haemorrhage occurs it is usually
sufficient to withdraw unfractionated or low molecular weight <span>heparin</span>, but if rapid reversal of the effects of the <span>heparin</span> is required, <span>protamine sulphate</span> (<a title=" Protamine sulphate" href="2799.htm#_2799">section 2.8.3</a>) is a specific antidote (but only partially
reverses the effects of low molecular weight heparins).</p></div></div></div></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_2762"><a href="2762.htm" title="HEPARIN">HEPARIN</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="2761.htm">Previous: 2.8.1 Parenteral anticoagulants</a> | <a class="top" href="11290.htm#">Top</a> | <a accesskey="]" href="2762.htm">Next: HEPARIN</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>